Free tool
FAERS Monitor: Cordran
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 016455 or its brand name (Cordran, Flurandrenolide). Reports on generic versions are filed under their own applications.
Reports
333
Serious
152
46% of reports
Hospitalization
43
Death reported
6
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pruritus31
- drug ineffective30
- headache20
- nausea20
- rash19
- fatigue18
- pain18
- diarrhoea16
- psoriasis16
- depression14
- dyspnoea14
- pain in extremity14
- off label use13
- anxiety12
- dizziness12
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 1 |
| 2006 | 4 |
| 2007 | 2 |
| 2009 | 1 |
| 2010 | 4 |
| 2011 | 6 |
| 2012 | 4 |
| 2013 | 9 |
| 2014 | 11 |
| 2015 | 24 |
| 2016 | 20 |
| 2017 | 31 |
| 2018 | 22 |
| 2019 | 31 |
| 2020 | 24 |
| 2021 | 18 |
| 2022 | 22 |
| 2023 | 27 |
| 2024 | 20 |
| 2025 | 22 |
| 2026 | 27 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,826 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| psoriasisSignal | 16 | 7.7 | 4.8 | 88 |
| pruritusSignal | 31 | 5.1 | 3.6 | 100 |
| depressionSignal | 14 | 3.9 | 2.3 | 27 |
| pain in extremitySignal | 14 | 3.0 | 1.8 | 17 |
| rashSignal | 19 | 2.8 | 1.8 | 20 |
| anxietySignal | 12 | 2.7 | 1.5 | 11 |
| headacheSignal | 20 | 2.0 | 1.3 | 10 |
| pain | 18 | 1.9 | 1.2 | 6 |
| nausea | 20 | 1.6 | 1.0 | 4 |
| diarrhoea | 16 | 1.6 | 1.0 | 3 |
| dyspnoea | 14 | 1.6 | 0.9 | 2 |
| dizziness | 12 | 1.5 | 0.9 | 2 |
| fatigue | 18 | 1.5 | 0.9 | 2 |
| drug ineffective | 30 | 1.4 | 1.0 | 4 |
| off label use | 13 | 0.9 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.